



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Ref: ADL/SE/2025-26/01
April 2, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

This is to inform you that the Company has received Cautionary e-mail/ letter from BSE Limited (BSE) and National Stock Exchange of India Limited (NSE). The requisite information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is given below:

Name of the Authority	BSE Limited (BSE) and National Stock Exchange of India Limited (NSE)
Nature and details of the action(s) taken or order(s) passed	The Company has received cautionary e-mail/ letter from BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) for delay in submission of intimation under Regulation 30 of Listing Regulations.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	April 1, 2025
Details of the violation(s) / contravention(s) committed or alleged to be committed	<p>As per Cautionary e-mail/ letter, the Company has not submitted the announcement dated July 17, 2024 within the prescribed timelines of 24 hours from receipt of order as per sub-para 20 of Para A of Part A of Schedule III of SEBI LODR.</p> <p>With reference to above, the Company shall ensure compliance with the regulations and exercise due caution to avoid recurrence of such events.</p>
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on financial, operational or other activities of the Company.



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

The additional information pursuant to Industry Standards Note on Regulation 30 of the Listing Regulations is provided under **Annexure A.**

As advised by Exchanges copy of the cautionary e-mail/ letter is attached herewith

This is for your information and records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M. No.: F12932



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Annexure A

April 2, 2025

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

In respect of the captioned matter, I, the undersigned, state and declare that the information and details provided in **Form A**, in compliance with Regulation 30(13) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, is true, correct and complete to the best of my knowledge and belief.

This is for your information and records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: F12932



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.: L37060MH1984PLC055433

Form A

Disclosure by Aarti Drugs Limited regarding receipt of communication from regulatory, statutory, enforcement or judicial authority under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

[Regulation 30(13) – Disclosure of communication from regulatory, statutory, enforcement or judicial authority]

Sr. No.	Particulars	Details
1.	Name of the listed company	Aarti Drugs Limited
2.	Type of communication received	Cautionary e-mail/ letter
3.	Date of receipt of communication	April 1, 2025
4.	Authority from whom communication received	BSE Limited (BSE) and National Stock Exchange of India Limited (NSE)
5.	Brief summary of the material contents of the communication received, including reasons for receipt of the communication	The Company has received cautionary e-mail/ letter from BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) for delay in submission of intimation under Regulation 30 of Listing Regulations.
6.	Period for which communication would be applicable, if stated	N.A
7.	Expected financial implications on the listed company, if any	There is no financial impact on the Company.
8.	Details of any aberrations/non-compliances identified by the authority in the communication	As per Cautionary e-mail/ letter, the Company has not submitted the announcement dated July 17, 2024 within the prescribed timelines of 24 hours from receipt of order as per sub-para 20 of Para A of Part A of Schedule III of SEBI LODR.
9.	Details of any penalty or restriction or sanction imposed pursuant to the communication	There is no penalty or restriction or sanction imposed.
10.	Action(s) taken by listed company with respect to the communication	The Company will exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars
11.	Any other relevant information	-

AARTIDRUGS - Cautionary Email

1 message

Tue, Apr 1, 2025 at 6:16 PM

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on July 17, 2024 regarding the order passed by Maharashtra Pollution Control Board dated July 13, 2024.

As per Regulation 30 read with sub-para 20 of Para A Part A of Schedule III of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in case of Action(s) taken or orders passed by any regulatory, statutory, enforcement authority or judicial body against the listed entity or its directors, key managerial personnel, senior management, promoter or subsidiary, in relation to the listed entity the said event shall be disclosed to the Stock Exchanges by the listed entities within 24 hours of receipt of order/action taken.

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of within 24 hours of receipt of order/action taken as per sub-para 20 of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.

Cautionary letter - Aarti Drugs Ltd (524348)

1 message

Tue, Apr 1, 2025 at 5:54 PM

CONFIDENTIAL

LIST/COMP/JP/6/2025-26

Date: April 1, 2025

To,
Company Secretary/ Compliance Officer

Aarti Drugs Ltd (524348)

-

Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on July 17, 2024 regarding the order received from Maharashtra Pollution Control Board (MPCB).

As per Regulation 30 read with Sub-para 20 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in case of Action(s) taken or orders passed by any regulatory, statutory, enforcement authority or judicial body against the listed entity or its directors, key managerial personnel, senior management, promoter or subsidiary, in relation to the listed entity, the said event shall be disclosed to the Stock Exchanges by the listed entities within 24 hours of receipt of the order /action taken.

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of within 24 hours of receipt of order/action taken as per sub-para 20 of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team

BSE Limited

P J Towers, Dalal Street,

Mumbai - 400001, India

www.bseindia.com

Tel: 022 2272 8561/8475